drugset / Trial / NCT07463573
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Timeline
- Start
- 2026-04-20
- Primary completion
- 2028-06-05
- Completion
- 2029-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | QLC5508 | Other / unclassified | — | — |